Literature DB >> 201408

E-rosette inhibiting substance in Hodgkin's disease spleen extracts.

M M Bieber, Z Fuks, H S Kaplan.   

Abstract

Patients with Hodgkin's disease often manifest impairment of cell-mediated immune responses in both in vivo and in vitro tests, as well as a markedly decreased percentage of E rosette-forming (T) lymphocytes in the peripheral blood. This report describes the inhibition of E-rosette formation by normal peripheral blood lymphocytes after incubation with extracts prepared from the spleens of patients with Hodgkin's disease. Such extracts also depressed E-rosette formation by the peripheral blood lymphocytes of patients with Hodgkin's disease after those cells had been restored to normal function by prior incubation in foetal calf serum. Similarly prepared extracts from the spleens of normal donors had no immunodepressive effect. The E-rosette inhibitory substance in the Hodgkin's disease spleen extracts was found to be a complex containing beta-lipoprotein, C-reactive protein, and C1q.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 201408      PMCID: PMC1541080     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.

Authors:  Z Fuks; S Strober; D P King; H S Kaplan
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

2.  Effect of large doses of an alpha2-glycoprotein fraction on the survival of rat skin homografts.

Authors:  J F MOWBRAY
Journal:  Transplantation       Date:  1963-01       Impact factor: 4.939

3.  An investigation of Hodgkin's disease with respect to the problem of homotransplantation.

Authors:  W D KELLY; D L LAMB; R L VARCO; R A GOOD
Journal:  Ann N Y Acad Sci       Date:  1960-05-31       Impact factor: 5.691

4.  Successful skin bomografts in mature non-littermate rats treated with fractions containing alpha-globulins.

Authors:  B B KAMRIN
Journal:  Proc Soc Exp Biol Med       Date:  1959-01

5.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

6.  Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients.

Authors:  R C Young; M P Corder; H A Haynes; V T DeVita
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

7.  Report of the Committee on Hodgkin's Disease Staging Classification.

Authors:  P P Carbone; H S Kaplan; K Musshoff; D W Smithers; M Tubiana
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

8.  Impaired lymphocyte function in untreated Hodgkin's disease.

Authors:  R Levy; H S Kaplan
Journal:  N Engl J Med       Date:  1974-01-24       Impact factor: 91.245

9.  Inhibition of transformation of normal lymphocytes by plasma factor from patients with Hodgkin's disease and cancer.

Authors:  P G Scheurlen; W Schneider; A Pappas
Journal:  Lancet       Date:  1971-12-04       Impact factor: 79.321

10.  CRYSTALLIZATION OF C-REACTIVE PROTEIN FOLLOWING REMOVAL OF ASSOCIATED LIPID-CONTAINING MATERIAL BY ANTISERUM TO NORMAL HUMAN BETA LIPOPROTEIN.

Authors:  H F WOOD
Journal:  Yale J Biol Med       Date:  1963-12
View more
  3 in total

Review 1.  The role of the spleen in leukemias and lymphomas including Hodgkin's disease.

Authors:  R Maurer
Journal:  Experientia       Date:  1985-02-15

2.  Platelet inhibitory effects of CRP preparations are due to a co-isolating low molecular weight factor.

Authors:  B A Fiedel; L A Potempa; M E Frenzke; R M Simpson; H Gewurz
Journal:  Immunology       Date:  1982-01       Impact factor: 7.397

3.  Impaired autologous mixed lymphocyte reactivity in Hodgkin's disease.

Authors:  M Begemann; G Claas; H Falke
Journal:  Klin Wochenschr       Date:  1982-01-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.